Fibrinolysin
Fibrinolysin: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Fibrinolysin
ATX code: B01AD05
Active ingredient: human fibrinolysin (Fibrinolysinum hominis)
Manufacturer: Biopharma (Ukraine)
Description and photo update: 2018-25-10
Fibrinolysin is an antithrombotic drug.
Release form and composition
The dosage form is a powder for preparation of a solution for injection: amorphous, white, hygroscopic [in ampoules of 300 units (units) of fibrinolytic activity, in vials of 20,000 units, in a cardboard box of 10 ampoules or 1 bottle].
The active substance contained in 1 ampoule / 1 bottle: fibrinolysin (human) - 300 U / 20,000 U, respectively.
Pharmacological properties
Pharmacodynamics
The active substance of the drug, fibrinolysin, is a component of human blood obtained by enzymatic activation of profibrinolysin in human plasma by trypsin. The activity of the agent is determined biologically by its ability to induce lysis of a fresh standard fibrin clot for half an hour at a temperature of 37 ºС.
Fibrinolysin refers to drugs that affect blood clotting. It is a physiological component of the body's natural anti-coagulation system.
The mechanism of action of the drug is associated with its ability to break down fibrin filaments (acts as a proteolytic enzyme). In pathological processes, accompanied by the formation of blood clots and the loss of fibrin clots, the greatest effect of the drug is achieved with its early use. With a longer existence of a thrombus, the effectiveness of the agent decreases.
Indications for use
Fibrinolysin in vials
- myocardial infarction;
- chronic thrombophlebitis in the acute phase;
- thromboembolism of cerebral vessels, pulmonary and peripheral arteries;
- acute thrombophlebitis.
Fibrinolysin ampoules
- thrombosis of veins / arteries (central ocular vessels) and their branches;
- hemorrhages in the retina, anterior chamber or vitreous body of the eye;
- hemorrhages in the organs of vision of traumatic genesis (not earlier than after 4 days from the time of intraocular injury).
Contraindications
Fibrinolysin in vials
Absolute:
- pulmonary tuberculosis in acute form;
- cirrhosis of the liver;
- acute hepatitis;
- peptic ulcer of the gastrointestinal tract;
- radiation sickness;
- fibrinogenopenia;
- nephritis;
- hemorrhagic diathesis;
- bleeding;
- open wound;
- excessively high blood pressure with brain damage;
- a history of anaphylactic reaction;
- recently transferred (10 days) surgery, biopsy, puncture of large vessels, trauma;
- childhood;
- pregnancy;
- period of breastfeeding;
- individual intolerance to the active substance of the drug.
A relative (a condition in the presence of which the prescription of a drug requires caution) contraindication to the use of the drug is an age over 70 years.
Fibrinolysin ampoules
Absolute:
- a history of anaphylactic reaction;
- simultaneous therapy with dicain;
- childhood;
- pregnancy;
- lactation period;
- individual intolerance to the active substance of the drug.
Relative (diseases / conditions in the presence of which the prescription of a drug requires caution):
- peptic ulcer of the gastrointestinal tract;
- cirrhosis of the liver;
- acute hepatitis;
- tuberculosis;
- nephritis;
- radiation sickness;
- hemorrhagic diathesis;
- fibrinogenopenia;
- bleeding;
- open wounds;
- excessive blood pressure with brain damage;
- recent trauma, surgery, biopsy, puncture of large vessels;
- age over 70 years.
Instructions for the use of Fibrinolysin: method and dosage
Fibrinolysin in vials
The solution prepared from the powder is administered by infusion. Before administration, the contents of the vial are diluted with 9% sodium chloride solution in the ratio of 100-160 U of powder per 1 ml of solvent. Next, heparin is added to the resulting solution at the rate of 10,000 U of heparin per 20,000 U of Fibrinolysin.
The rate of administration of the drug at the beginning is 10–12 drops per minute. With good tolerance, it can be increased to 15–20 drops in 1 min. The total daily dose varies from 20,000 to 40,000 U, the duration of the infusion should not be less than 3 hours. Since Fibrinolysin does not contain a stabilizer, the prepared solution quickly loses its activity.
After the infusion of a solution of Fibrinolysin with Heparin is completed, continue intravenous or intramuscular injections of one Heparin in a daily dose of 40,000-60,000 IU for 2-3 days. Further, the daily dose of Heparin is successively reduced and the patient is transferred to the administration of indirect anticoagulants.
Duration of drug use:
- cerebral vascular thrombosis and myocardial infarction: during the first 6 hours;
- peripheral arterial thrombosis: within 12 hours;
- peripheral vein thrombosis: within 5-7 days from the moment of detection of thrombosis.
Fibrinolysin ampoules
The solution prepared from the powder is injected subconjunctivally: under the conjunctiva of the lower transitional fold or sclera after preliminary introduction into the conjunctival sac of 0.5% Dikain (for anesthesia). Before use, the contents of 1 ampoule are diluted in 0.5 ml of water for injection.
Re-introduction is carried out after 1–2 days. The total number of injections, depending on the indications, varies from 3 to 10.
Side effects
Fibrinolysin in vials
- allergic reactions, including urticaria, fever, facial flushing;
- lowering blood pressure (requires monitoring during administration);
- pain in the abdomen and / or chest;
- bleeding;
- pain / changes at the infusion site.
Fibrinolysin ampoules
- allergic reactions, including urticaria, local edema, facial flushing;
- pain / changes at the injection site.
Overdose
Fibrinolysin in vials
The main symptoms: bleeding (with intravenous administration of high doses of the drug).
Therapy: withdrawal of therapy, intravenous infusion of aminocaproic acid and plasma.
special instructions
With the development of side effects, the rate of administration (for the drug in vials) or the dose (for the drug in ampoules) of Fibrinolysin is reduced, and in cases of severe reactions, the therapy is canceled. To stop side effects, depending on their direction, antihistamines or cardiovascular agents, promedol are administered.
Drug treatment is carried out under close monitoring of blood coagulation.
Immediately after the infusion of the solution, the amount of fibrinogen is determined (indicators should be at least 100%), blood coagulation time (indicators should not increase more than 2 times), prothrombin level (indicators should not decrease by more than 30-40%).
Application during pregnancy and lactation
The drug is contraindicated for use during pregnancy and lactation.
Pediatric use
Fibrinolysin is contraindicated for use in children.
With impaired renal function
Fibrinolysin in vials is contraindicated in nephritis.
In ampoules, the drug is prescribed with caution to patients with nephritis.
For violations of liver function
Fibrinolysin in vials is contraindicated in liver cirrhosis and acute hepatitis.
In ampoules, the drug is prescribed with caution to patients with liver cirrhosis and acute hepatitis.
Use in the elderly
According to the instructions, Fibrinolysin is prescribed with caution to patients over the age of 70.
Drug interactions
There are no data on interactions with other drugs.
Analogs
Fibrinolysin analogues are: Trombovazim, Biostrepta, Metalise, Elaxim, Tobarpin, Streptokinase, Zigris, Eberkinase, Gemaza, Aktilize, Distreptase, Celiasis.
Terms and conditions of storage
Store in a place protected from light and moisture at temperatures up to 8 ° C. Keep out of the reach of children.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews of Fibrinolysin
There are no reviews of Fibrinolysin, since the drug is not available in pharmacies.
Fibrinolysin price in pharmacies
The price of Fibrinolysin is unknown, since the drug is not available in pharmacies. In the presence of group analogs: Metallize lyophilisate for the preparation of a solution for intravenous administration (50 mg in vials) - 42 840 rubles; Hemaza lyophilisate for the preparation of a solution for injection (5 thousand international units in 1 ml, 5 ampoules in a package of 1 ml) - 969 rubles.
Maria Kulkes Medical journalist About the author
Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
